Growth Hormone News and Research RSS Feed - Growth Hormone News and Research

Growth hormone (GH) is a protein-based peptide hormone. It stimulates growth, cell reproduction and regeneration in humans and other animals. Growth hormone is a 191-amino acid, single-chain polypeptide that is synthesized, stored, and secreted by the somatotroph cells within the lateral wings of the anterior pituitary gland.
Weekly growth hormone on course for phase III in children

Weekly growth hormone on course for phase III in children

A long-lasting formulation of human growth hormone appears to be as effective as standard daily treatment in paediatric patients with growth hormone deficiency, researchers reported at the European Society of Paediatric Endocrinology annual meeting in Dublin, Ireland. [More]
Nutritional supplement boosts growth in short, lean children

Nutritional supplement boosts growth in short, lean children

A balanced nutritional supplement promotes height and weight gain in lean prepubertal children with idiopathic short stature, show the findings of a randomised trial. [More]
New method helps reveal secret dance of proteins

New method helps reveal secret dance of proteins

Staying clear of diseases requires that the proteins in our cells cooperate with one another. But, it has been a well-guarded secret how tens of thousands of different proteins find the correct dancing partners as they degrade and build up the human body, brain and nervous system. [More]
Scientists crack genetic code of liver fluke parasite

Scientists crack genetic code of liver fluke parasite

Singapore-An international team of scientists from Singapore, Thailand, China and Australia has cracked the genetic code of the liver fluke parasite, Opisthorchis viverrini, using a unique DNA analysis technique developed at A*STAR's Genome Institute of Singapore (GIS). [More]
ANP reports primary efficacy results from ATL1103 Phase II trial in patients with acromegaly

ANP reports primary efficacy results from ATL1103 Phase II trial in patients with acromegaly

Antisense Therapeutics Limited is pleased to report the primary efficacy results from its Phase II clinical trial of ATL1103 in patients with the potentially life threatening growth disorder, acromegaly. [More]
Acromegaly and antisense therapy: an interview with Mark Diamond, CEO Antisense Therapeutics

Acromegaly and antisense therapy: an interview with Mark Diamond, CEO Antisense Therapeutics

Acromegaly is a chronic, life-threatening disease triggered by a benign tumour of the pituitary gland causing excessive growth hormone release. Oversupply of growth hormone stimulates liver, fat and kidney cells to produce excess levels of Insulin-Like Growth Factor I (IGFI), which causes abnormal growth of the bones of the hands, face and feet and bodily organs. [More]
Inovio Pharmaceuticals reports increased revenue in second quarter 2014

Inovio Pharmaceuticals reports increased revenue in second quarter 2014

Inovio Pharmaceuticals, Inc. today reported financial results for the quarter ended June 30, 2014. Total revenue was $3.8 million and $6.2 million for the three and six months ended June 30, 2014, compared to $786,000 and $2.2 million for the same periods in 2013. [More]
Aeterna Zentaris signs strategic co-promotion services agreement with ASCEND

Aeterna Zentaris signs strategic co-promotion services agreement with ASCEND

Aeterna Zentaris Inc. today announced a strategic co-promotion services agreement with ASCEND Therapeutics US, LLC. [More]
New toolkits help young adults navigate shift from pediatric to adult health care

New toolkits help young adults navigate shift from pediatric to adult health care

For young adults who have been diagnosed with a chronic condition like Type 1 diabetes or growth hormone deficiency, health concerns can add a degree of difficulty to transitions like leaving for college or living alone for the first time. [More]
Drug for reduction of abdominal fat in HIV patients may also reduce fatty liver disease

Drug for reduction of abdominal fat in HIV patients may also reduce fatty liver disease

The only drug to receive FDA approval for reduction of the abdominal fat deposits that develop in some patients receiving antiviral therapy for HIV infection may also reduce the incidence of fatty liver disease in such patients. [More]
Growth hormone reduces liver fat in HIV-infected patients with excess abdominal fat

Growth hormone reduces liver fat in HIV-infected patients with excess abdominal fat

In a preliminary study, HIV-infected patients with excess abdominal fat who received the growth hormone-releasing hormone analog tesamorelin for 6 months experienced modest reductions in liver fat, according to a study in the July 23/30 issue of JAMA, a theme issue on HIV/AIDS. [More]
Marmoset's unique rapid reproductive system sheds new light on evolution and primate biology

Marmoset's unique rapid reproductive system sheds new light on evolution and primate biology

A team of scientists from around the world led by Baylor College of Medicine and Washington University in St. Louis has completed the genome sequence of the common marmoset - the first sequence of a New World Monkey - providing new information about the marmoset's unique rapid reproductive system, physiology and growth, shedding new light on primate biology and evolution. [More]
Dosing commences in Essentialis’ DCCR clinical study in obese Prader-Willi syndrome patients

Dosing commences in Essentialis’ DCCR clinical study in obese Prader-Willi syndrome patients

Essentialis announced today the dosing of the first patient in clinical study PC025, which is designed to evaluate the safety and efficacy of diazoxide choline controlled release tablets (DCCR) in obese Prader-Willi syndrome patients. [More]
New study finds that GH treatment could lead to depression in children

New study finds that GH treatment could lead to depression in children

Short, otherwise healthy children who are treated with growth hormone (GH) may become taller, but they may also become more depressed and withdrawn over time, compared to children the same age and height who are not treated with GH, a new study finds. [More]
Growth hormone deficiency may protect people from developing Type 2 diabetes, cancer

Growth hormone deficiency may protect people from developing Type 2 diabetes, cancer

People who lack growth hormone (GH) receptors also appear to have marked insulin sensitivity that prevents them from developing diabetes and lowers their risk for cancer, despite their increased percentage of body fat, new research finds. [More]

Childhood oestrogen may normalise thelarche in Turner syndrome

Treating girls with Turner syndrome with low-dose oestrogen from childhood results in earlier thelarche and a slower tempo of puberty, research shows. [More]
‘Surprising’ effect of growth hormone on BMI in normal-weight children

‘Surprising’ effect of growth hormone on BMI in normal-weight children

Researchers have found that the body mass index standard deviation score increases in normal-weight children receiving growth hormone treatment. [More]
Growth hormone levels may manifest in signs of aging

Growth hormone levels may manifest in signs of aging

The decreased production of growth hormone is caused by a physiological process known as somatopause, which practically affects the entire body, since it's involved in body composition, metabolism, bone mineral density and cardiovascular function. [More]
USPTO grants two additional patents to SeroVital-hgh formula

USPTO grants two additional patents to SeroVital-hgh formula

SeroVital®-hgh, the "Fountain of Youth" Formula everyone's talking about, has been making headlines ever since a group of some of the most renowned researchers in the world revealed that this oral compound is actually capable of increasing mean, endogenous, serum (blood) human growth hormone (hGH) levels by 682%. Experts everywhere — from dermatologists and obesity researchers to women's healthcare providers and even the famed Dr. Oz himself — began paying attention to this groundbreaking formula. [More]
Antares Pharma reports total revenues of $5.2 million for first quarter 2014

Antares Pharma reports total revenues of $5.2 million for first quarter 2014

Antares Pharma, Inc. today reported operating and financial results for the first quarter ended March 31, 2014. [More]